Papilloma viral infection – Diagnostics – Overview of Information and Clinical Research

Diagnosing human papillomavirus (HPV) infection requires understanding when to seek testing and what methods healthcare providers use to detect the virus and its health effects. While HPV itself often causes no symptoms, recognizing when diagnostic testing is necessary can help prevent serious health complications, including various types of cancer.

Introduction: When to Seek HPV Diagnostics

Human papillomavirus is an extremely common viral infection, with most sexually active people encountering it at some point in their lives. Because HPV typically causes no symptoms, many people never realize they have been infected. The virus often clears from the body naturally within two years without any intervention or health problems. However, certain situations make diagnostic testing important and advisable.^[1]^[3]

Women should begin regular cervical screening around age 21, even if they have no symptoms. This screening becomes particularly important because HPV is the main cause of cervical cancer, and early detection of cell changes can prevent cancer from developing. For women aged 30 and older, testing for HPV becomes a standard part of cervical cancer screening. If you are in this age group, your healthcare provider will likely include HPV testing along with your regular Pap smear (a test that collects cells from the cervix to check for abnormalities).^[1]^[9]

You should seek diagnostic evaluation if you notice any unusual growths, lumps, or bumps in your genital area, around your anus, or in your mouth or throat. These visible changes could indicate genital warts, which are caused by certain types of HPV. While genital warts themselves are not dangerous and do not lead to cancer, they require medical attention for proper diagnosis and treatment options. Healthcare providers can usually identify genital warts through visual examination, though they may perform additional tests to confirm the diagnosis.^[2]^[11]

⚠️ Important

If you test positive for HPV, this does not necessarily mean you or your partner has been unfaithful. HPV can remain dormant in your body for months or even many years before causing any detectable changes. There is no way to determine when the infection occurred or from which partner it came. The virus is so common that having HPV is considered a natural consequence of being sexually active.

People who are immunosuppressed, such as those living with HIV or taking medications that weaken the immune system, may need more frequent screening and monitoring. The immune system normally controls HPV infections, but when immunity is compromised, the virus is more likely to persist and cause health problems. If you fall into this category, discuss appropriate screening schedules with your healthcare provider.^[4]

Classic Diagnostic Methods for HPV

Healthcare providers use several different approaches to diagnose HPV infection and the conditions it causes. The specific tests used depend on what symptoms are present, your age, your sex, and which parts of the body might be affected.

Visual Examination

The simplest diagnostic method is visual inspection. Healthcare providers can often diagnose genital warts simply by looking at them. Genital warts have distinctive appearances – they may look like small bumps, flat growths, or cauliflower-like clusters. They can appear on the vulva, vagina, cervix, penis, scrotum, or around the anus. In some cases, warts may also develop in the mouth or throat. While visual examination is straightforward for obvious warts, it cannot detect HPV infections that cause no visible symptoms.^[2]^[10]

Acetic Acid Test

When genital warts are not easily visible to the naked eye, healthcare providers may apply a vinegar solution containing acetic acid (a mild acid found in vinegar) to the genital areas. This solution temporarily turns areas infected with certain types of HPV white, making flat lesions that would otherwise be invisible become visible. This test helps identify subtle changes that might otherwise be missed during routine examination. However, this test is not used for routine screening and is typically reserved for situations where the provider suspects HPV infection but cannot see obvious signs.^[10]

Cervical Screening Tests

For women, cervical screening represents the most important diagnostic tool for detecting HPV-related cell changes that could lead to cancer. Two main types of tests are used during cervical screening: the Pap smear and the HPV test itself.

During a Pap smear (also called a Papanicolaou smear), a healthcare provider collects a small sample of cells from the cervix using a brush or small spatula. This sample is sent to a laboratory where specialists examine the cells under a microscope to look for abnormal changes. These abnormal cells, if found, indicate cervical dysplasia (abnormal cell changes on the cervix), which can be a precursor to cervical cancer. The Pap smear does not test for HPV directly but looks for the cellular changes that HPV can cause.^[1]^[8]

The HPV DNA test uses a similar sample of cervical cells but looks for the genetic material of high-risk HPV types. This test can identify whether you are infected with HPV types that are most likely to cause cancer, particularly types 16 and 18, which account for the majority of cervical cancers. For women under age 30, HPV testing is typically only done if a Pap smear shows abnormal results. This is because HPV infections are very common in younger women but usually resolve on their own. For women aged 30 and older, HPV testing is often performed alongside the Pap smear as part of routine screening.^[1]^[10]

As of recent updates in some countries, including parts of New Zealand, the primary cervical screening test has shifted to HPV testing using a vaginal swab. This approach looks specifically for high-risk HPV types. If the HPV test is positive, meaning high-risk HPV types are detected, further testing is then discussed with healthcare providers to assess the risk of cervical abnormalities or cancer.^[7]

Colposcopy and Biopsy

When screening tests show abnormal results, your healthcare provider may recommend additional diagnostic procedures. A colposcopy (a procedure to closely examine the cervix using a special magnifying instrument) allows the provider to look at the cervix in detail. During this examination, the provider uses a device called a colposcope, which provides a magnified view of the cervix. If suspicious areas are identified, the provider may take a small tissue sample, called a biopsy (removal of a small piece of tissue for examination under a microscope), to determine whether precancerous changes or cancer are present.^[1]

Testing Limitations

It is important to understand that HPV testing has limitations. There is no general HPV blood test available. HPV testing specifically checks for high-risk types associated with cancer, primarily in cervical cells. For men, there is no routine HPV screening test approved for general use. Men typically only receive HPV-related diagnoses when they develop visible genital warts or, in rare cases, when they develop cancers linked to HPV, such as penile, anal, or throat cancers.^[7]^[11]

Testing for low-risk HPV types that cause genital warts is not routinely performed because the warts themselves are usually diagnosable through visual examination. Additionally, testing for HPV when there are no symptoms or visible changes is generally not recommended. This is because HPV is so common that most people will test positive at some point, yet the majority of infections clear naturally without causing any health problems. Testing in the absence of symptoms could cause unnecessary worry without providing useful medical information.^[7]^[15]

Screening for Other HPV-Related Cancers

While cervical cancer screening is well-established, screening for other cancers caused by HPV is less routine. For anal cancer, which is associated with HPV, screening may be recommended for people at higher risk, such as men who have sex with men, people living with HIV, or women with a history of cervical or vulvar abnormalities. Anal Pap smears, similar in concept to cervical Pap smears, can be performed to check for abnormal cells in the anal area.^[5]

There is currently no standard screening test for HPV-related throat cancers. These cancers are typically diagnosed when symptoms appear, such as persistent sore throat, difficulty swallowing, or lumps in the neck. Diagnosis usually involves examination by a specialist and may include biopsies of suspicious tissue.^[5]

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments or preventive measures for HPV-related conditions require specific diagnostic criteria to determine who can participate. These criteria ensure that participants have the appropriate medical conditions being studied and that researchers can accurately measure the effects of interventions.

For trials focused on preventing HPV infection or its complications, participants may need to undergo baseline HPV testing to confirm whether they are currently infected with HPV and, if so, which types. HPV DNA typing tests can identify specific HPV strains, which is important because trials may target particular high-risk or low-risk types. Women participating in cervical cancer prevention trials typically need cervical screening, including both Pap smears and HPV tests, to establish baseline cervical health status.^[4]

Clinical trials evaluating treatments for genital warts require visual confirmation of warts and may include measurements or photographic documentation of the size, number, and location of warts. This baseline assessment allows researchers to track whether treatments effectively reduce or eliminate warts over time.

For studies examining treatments for precancerous lesions or early-stage cancers caused by HPV, participants must have histological confirmation through biopsy. This means tissue samples must be examined under a microscope to verify the diagnosis and determine the grade or stage of the abnormality. Colposcopy is often required as part of the screening process to identify and sample suspicious areas accurately.

Some clinical trials may also require participants to undergo imaging tests, such as CT scans, MRI scans, or PET scans, particularly when studying treatments for HPV-related cancers. These imaging tests help determine the extent of disease spread and provide baseline measurements for evaluating treatment effectiveness.^[4]

Blood tests may be required to assess overall health status and ensure participants can safely undergo the study interventions. These might include tests for immune system function, liver and kidney function, and blood cell counts. For vaccine trials aimed at preventing HPV infection, antibody tests may be used to measure immune response to the vaccine.

⚠️ Important

Clinical trial participation requires meeting specific eligibility criteria based on diagnostic test results. If you are interested in participating in an HPV-related clinical trial, discuss with your healthcare provider whether your current health status and diagnostic results match the requirements of available studies. Each trial has unique criteria regarding HPV type, disease stage, previous treatments, and other health factors.

Prognosis and Survival Rate

Prognosis

The outlook for people with HPV infection varies greatly depending on several factors. Most importantly, the vast majority of HPV infections have an excellent prognosis because the body’s immune system naturally clears the virus. Approximately 90% of HPV infections resolve on their own within two years without causing any health problems or requiring treatment. This means that for most people, HPV infection is a temporary condition that causes no lasting effects.^[3]^[5]

For those who develop genital warts caused by low-risk HPV types, the prognosis remains generally good. While warts can be uncomfortable and may recur even after treatment, they do not progress to cancer. Many warts disappear on their own within a year, though treatment can speed this process. The main concern with genital warts is cosmetic and psychological rather than life-threatening.^[16]^[19]

The prognosis becomes more serious when high-risk HPV types persist and cause precancerous cell changes. However, even in these cases, the outlook is typically very good if the changes are detected early through regular screening. Precancerous changes, such as cervical dysplasia, can be successfully treated before they progress to cancer. The progression from HPV infection to precancerous changes and then to cancer typically takes many years or even decades, providing ample opportunity for detection and intervention through screening programs.^[1]^[9]

Several factors affect prognosis for persistent HPV infection and progression to disease. Age plays a significant role – younger people under 30 are much more likely to clear HPV infections naturally compared to older individuals. Immune system function is another critical factor. People with weakened immune systems, whether due to HIV infection, immunosuppressive medications, or other conditions, are more likely to have persistent HPV infections and faster progression to precancerous changes or cancer. Smoking, long-term use of oral contraceptives, and multiple childbirths can increase the risk of cervical cancer development in women with persistent high-risk HPV infection.^[4]^[17]

For HPV-related cancers, prognosis depends on the type of cancer, the stage at diagnosis, and how quickly treatment begins. Cervical cancer detected at an early stage through screening has excellent survival rates with appropriate treatment. Similarly, early detection of other HPV-related cancers improves outcomes significantly. This underscores the importance of regular screening and seeking medical attention for unusual symptoms.^[1]

Survival Rate

Survival rates for HPV-related conditions vary significantly depending on what health problem develops from the infection. For the overwhelming majority of people with HPV – those whose immune system clears the infection naturally – there is no impact on survival. These individuals never develop any disease from HPV.^[3]

For cervical cancer, survival rates are closely tied to the stage at diagnosis. Nearly all cervical cancers are caused by HPV, with types 16 and 18 accounting for approximately 70% of cases. When cervical abnormalities are detected and treated at the precancerous stage through screening programs, progression to invasive cancer can be prevented entirely. For early-stage cervical cancer that has been detected through screening, treatment outcomes are generally very favorable, though specific survival statistics depend on numerous individual factors including the exact stage and grade of cancer, treatment approach, and patient characteristics.^[1]^[5]

Each year in the United States, HPV causes approximately 36,000 cases of cancer in both men and women, affecting various body sites including the cervix, vagina, vulva, penis, anus, and oropharynx (back of the throat, including the base of the tongue and tonsils). HPV type 16 is responsible for almost 90% of HPV-related cancers of the mouth, throat, or tonsils. Between 60% and 90% of other cancers at various sites are also linked to HPV infection.^[3]^[5]

The key message regarding survival is that early detection dramatically improves outcomes. Regular cervical screening for women, which includes both Pap smears and HPV testing, allows for detection of precancerous changes when they are most treatable. This screening approach has significantly reduced cervical cancer rates in countries where it is widely implemented. Getting vaccinated against HPV before exposure to the virus provides additional protection against the HPV types that cause most cancers and genital warts, further improving long-term health outcomes.^[1]^[12]

#1 Clinical Trials Search in Europe